Subscribe
shutterstock_529658371_lazyllama
lazyllama / Shutterstock.com
26 May 2022Big PharmaMuireann Bolger

UK regulators no longer exempt from paying successful parties' costs

The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority (CMA) should be required to pay the costs of a party successfully appealing against one of their infringement decisions.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Antitrust regulators to increase scrutiny of biosimilar deals
4 February 2020   US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.
Americas
US regulators sue ‘pharma bro’ Shkreli over drug monopoly
28 January 2020   The US Federal Trade Commission and New York’s attorney general have sued incarcerated ‘pharma bro’ Martin Shkreli for allegedly monopolising the market for life-saving drug Daraprim.
Big Pharma
Competition watchdog fines big pharma duo £70m
22 July 2022   The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Antitrust regulators to increase scrutiny of biosimilar deals
4 February 2020   US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.
Americas
US regulators sue ‘pharma bro’ Shkreli over drug monopoly
28 January 2020   The US Federal Trade Commission and New York’s attorney general have sued incarcerated ‘pharma bro’ Martin Shkreli for allegedly monopolising the market for life-saving drug Daraprim.
Big Pharma
Competition watchdog fines big pharma duo £70m
22 July 2022   The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.

More on this story

Americas
Antitrust regulators to increase scrutiny of biosimilar deals
4 February 2020   US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.
Americas
US regulators sue ‘pharma bro’ Shkreli over drug monopoly
28 January 2020   The US Federal Trade Commission and New York’s attorney general have sued incarcerated ‘pharma bro’ Martin Shkreli for allegedly monopolising the market for life-saving drug Daraprim.
Big Pharma
Competition watchdog fines big pharma duo £70m
22 July 2022   The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court